Future directions in the treatment of osteosarcoma
- 1 February 2016
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in Pediatrics
- Vol. 28 (1), 26-33
- https://doi.org/10.1097/mop.0000000000000298
Abstract
Purpose of review Overall survival rates for osteosarcoma have remained essentially unchanged over the past 3 decades despite attempts to improve outcome via dose intensification and modification based on response. This review describes recent findings from contemporary clinical trials, advances in the comprehension of osteosarcoma biology and genomic complexity, and potential opportunities using targeted and immune-mediated therapies. Recent findings Recent results from international collaborative trials have failed to demonstrate an ability to improve outcomes using a design in which the randomized question is dictated based on histologic response to preoperative chemotherapy. Novel prognostic markers assessable at diagnosis are vital to identifying subsets of osteosarcoma. Clinical trials focus has now shifted to serial phase II studies of novel agents to evaluate for activity in recurrent and refractory disease. In-depth analyses have revealed profound genomic instability and heterogeneity across patients, with nearly universal TP53 aberration. Although driver mutational events have not clearly been established, frequent derangements in specific pathways may suggest opportunities for therapeutic exploitation. Genomic complexity may lend support to a role for immune-mediated therapies. Summary Rigorous preclinical investigations are potentially generating novel strategies for the treatment of osteosarcoma that will inform the next generation of clinical trials, with the opportunity to identify agents that will improve survival outcomes.Keywords
This publication has 45 references indexed in Scilit:
- Immunotherapy of Childhood SarcomasFrontiers in Oncology, 2015
- Ganglioside GD2 expression is maintained upon recurrence in patients with osteosarcomaClinical Sarcoma Research, 2015
- Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcomaProceedings of the National Academy of Sciences of the United States of America, 2014
- A summary of the osteosarcoma banking efforts: A report from the Children's Oncology Group and the QuadW FoundationPediatric Blood & Cancer, 2014
- Programmed Cell Death Ligand 1 Expression in OsteosarcomaCancer Immunology Research, 2014
- Aerosol interleukin‐2 induces natural killer cell proliferation in the lung and combination therapy improves the survival of mice with osteosarcoma lung metastasisPediatric Blood & Cancer, 2014
- A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group studyAnnals of Oncology, 2011
- Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival—A Report From the Children's Oncology GroupJournal of Clinical Oncology, 2008
- Osteosarcoma: A Randomized, Prospective Trial of the Addition of Ifosfamide and/or Muramyl Tripeptide to Cisplatin, Doxorubicin, and High-Dose MethotrexateJournal of Clinical Oncology, 2005
- Alternative lengthening of telomeres is associated with chromosomal instability in osteosarcomasOncogene, 2001